MNTA: "Does the FDA's acceptance of the application as a 505(j) shed any light on how they view MNTA's technology? There are analysts out defending TEVA stating that generic Copaxone will likely fall under the new biologics legislation..."
I would characterize it as a "positive," wouldn't you? Of course the analysts will defend whatever position benefits their clients, although (as MNTA has learned via the Lovenox application) anything is possible in such gray areas of the FDA.
Market Data 
Markets 
AI
